Heron Therapeutics (HRTX) news

Omron aims to build physical AI platform that uses AI running on industrial computers to operate machinery & robots in coordination - Nikkei

Omron, a Japanese automation and industrial equipment manufacturer, is developing a physical AI platform designed to integrate artificial intelligence with industrial computing systems to coordinate the operation of machinery and robots. According to a report by Nikkei , the initiative aims to…

Japan's Onron to buy OnLogic for around 100B yen: Nikkei

Heron Therapeutics - License agreement has initial ten-year term with automatic two-year renewals - SEC filing

Heron Therapeutics, Inc. (DE) has disclosed in a recent SEC filing that a key license agreement is structured with an initial ten-year term , followed by automatic two-year renewal periods. The terms of the agreement were outlined in a Form S-3 filed on September 9, 2025. While the filing does not…

Heron Therapeutics - Granted exclusive license to market products in U.S. - SEC filing

Heron Therapeutics, Inc. (Nasdaq: HRTX) has reached a settlement with Mylan Pharmaceuticals, Inc. regarding the patent litigations for CINVANTI® and APONVIE®. As part of the agreement, Heron granted Mylan an exclusive license to market generic versions of these products in the United States, with…

Heron Therapeutics - Enters multi-product development and license agreement on Sept 23, 2026 - SEC filing

On September 23, 2026, Heron Therapeutics, Inc. (HRTX) announced the execution of a multi-product development and license agreement, as disclosed in a recent SEC filing. The agreement, which spans multiple therapeutic areas, is expected to expand the company’s portfolio and enhance its long-term…